Save Product
Product Details
Source
Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (SPD-M128) is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
Clone
AM128
Isotype
Human IgG1 | Kappa
Conjugate
Unconjugated
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA0.1-25 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) with a linear range of 0.05-0.78 ng/mL (QC tested).
Protocol
Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.197 μg/mL (Routinely tested).
Protocol
Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody (Cat. No. SPD-M128) was incubated with SARS-CoV-2 pseudotyped virus at 37 °C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37 °C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 0.03255 nM using the Reed-Muench method.
Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat.No. SPD-M128) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD:ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1 mutant and treated with the antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Protocol
Bioactivity-BLI
Loaded Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) on AHC Biosensor, can bind SARS-CoV-2 S1 protein, His Tag with an affinity constant of 4.42 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing